Cisplatin and Docetaxel Treatment Regimen for Lung Cancer

Cisplatin + docetaxel chemotherapy for lung cancer is a platinum-based doublet chemotherapy protocol used particularly to treat non-small cell lung cancer (NSCLC). This regimen aims to stop tumor cell growth and slow cancer spread.

Cisplatin

• Cisplatin is a platinum-based cytotoxic chemotherapy agent with alkylating effects. It forms covalent bonds within DNA strands (particularly cross-links between guanine nucleotides), disrupting DNA replication and transcription. When DNA repair mechanisms cannot correct this damage, apoptosis (programmed cell death) is induced.
• Its antitumor effect is more pronounced in rapidly dividing cells.
• Its most common toxicities include nephrotoxicity, ototoxicity, neurotoxicity and emetogenic effects (severe nausea-vomiting).
• Because of its renal toxicity, intravenous hydration is mandatory before and after treatment.
• It is often combined with other cytotoxic agents because cisplatin acts synergistically with drugs active at different phases of the cell cycle.

Docetaxel

• Docetaxel is an antimitotic taxane that affects microtubule dynamics, arresting cell division in the mitotic phase. Normally, microtubules polymerize to initiate cell division and then depolymerize and disassemble; docetaxel stabilizes this dynamic structure and prevents microtubule disassembly. This results in mitotic arrest followed by apoptosis.
• Its main adverse effects include bone marrow suppression (particularly neutropenia), alopecia, mucositis and peripheral neuropathy.
• Corticosteroid premedication (usually dexamethasone) is required because severe hypersensitivity reactions and fluid retention may develop.

The cisplatin-docetaxel combination is a regimen with established efficacy, particularly in non-small cell lung cancer (NSCLC). Because the agents act at different stages of the cell cycle, combining them increases tumor cell eradication.

Treatment Goals

Elimination of Tumor Cells (Cytotoxic Effect)

Cisplatin and docetaxel stop tumor cell growth through different mechanisms and initiate apoptosis (programmed cell death). This reduces tumor burden and slows disease progression.

Control of Tumor Growth and Metastasis

Treatment aims to prevent local tumor growth or spread to distant organs (metastasis). This is critical both for disease control and for extending survival.

Elimination of Microscopic Disease After Surgery (Adjuvant Goal)

If the primary tumor has been surgically removed, this chemotherapy regimen may be used to destroy remaining microscopic tumor cells, reducing the risk of recurrence.

Symptom Relief and Improved Quality of Life (Palliative Goal)

In advanced or metastatic disease, chemotherapy may reduce tumor burden and relieve symptoms such as cough, shortness of breath and pain. This is important for improving the patient's quality of life.

Combination with Other Treatments

In certain situations, cisplatin + docetaxel may be combined with immunotherapy (e.g., anti-PD-1/PD-L1 antibodies) or radiotherapy. This aims to improve treatment response and achieve long-term disease control.

Treatment Indications

Metastatic (Stage IV) Non-Small Cell Lung Cancer

• If the disease has spread to other parts of the body (bone, brain, liver, etc.), this regimen is given as systemic treatment.
• Treatment goal: Reduce tumor burden, extend survival and control symptoms (palliative intent).

Locally Advanced (Stage III) NSCLC

• Used when the tumor cannot be surgically removed but remains regionally confined.
• May be administered with or following chemoradiotherapy.
• Treatment goal: Reduce tumor size and achieve local disease control.

Adjuvant Treatment (After Surgery)

• Used to eliminate microscopic residual disease after surgical removal of the primary tumor.
• Particularly preferred in stage II or IIIA patients with lymph node involvement.
• Treatment goal: Reduce recurrence risk and achieve cure.

Neoadjuvant Treatment (Before Surgery)

• May be given before surgery in selected patients to shrink the tumor and improve surgical success.
• This approach is increasingly being used in clinical trials.

Combination with Immunotherapy (Selected Cases)

• In patients with low PD-L1 expression, immunotherapy (e.g., pembrolizumab) may be given with chemotherapy.
• Treatment goal: Strengthen tumor control by stimulating the immune system in addition to chemotherapy.

Situations Unsuitable for Treatment

Poor Performance Status (ECOG ≥ 2–3)

• This aggressive regimen cannot be tolerated by patients in poor general condition, those who are bedridden or unable to perform daily activities independently.
• Less intensive regimens or supportive (palliative) care alone are preferred for these patients.

Severe Renal Impairment

• Cisplatin is nephrotoxic and may cause serious harm in patients with impaired kidney function.
• Cisplatin is generally not given when creatinine clearance is < 50–60 mL/min; carboplatin may be considered as an alternative.

Severe Bone Marrow Suppression (Myelosuppression)

• With severe neutropenia, thrombocytopenia or anemia, this regimen may increase the risk of life-threatening infections.
• Hematologic parameters should be stable before treatment begins.
• Severe Neuropathy
• Particularly if peripheral neuropathy (numbness, burning in the hands/feet) is already present, docetaxel may worsen it.
• For patients with grade 2 or higher neuropathy, consider dose reduction or switching to alternative agents.

History of Severe Allergic Reactions

• These drugs should not be reused if a severe allergic reaction to taxanes (e.g., paclitaxel or docetaxel) or platinum compounds (e.g., cisplatin, carboplatin) has previously occurred.
• Different chemotherapy combinations are preferred for these patients.

Liver Impairment (Particularly for Docetaxel)

• Because docetaxel is metabolized in the liver, the risk of toxicity increases in patients with elevated bilirubin or AST/ALT.
• Patients with abnormal liver function tests require dose adjustment, or treatment may be contraindicated.

Older Age and Frailty

• In patients aged 75 or older, comorbidities and functional capacity should be carefully assessed.
• Less toxic treatments are preferred over this regimen in frail older patients.

Pregnancy and Breastfeeding

• Cisplatin and docetaxel are teratogenic (toxic to the fetus).
• Use during pregnancy is strictly contraindicated. Effective contraception is mandatory.

SGK Reimbursement Status

Cisplatin and docetaxel chemotherapy for lung cancer is covered by SGK.

Dosing Interval

• Cisplatin + docetaxel chemotherapy for lung cancer is commonly given every 21 days. In the standard protocol, cisplatin 75 mg/m² and docetaxel 75 mg/m² are given intravenously on the first day of treatment. The cycle is generally repeated for 4 to 6 cycles. Dosing intervals may be individualized according to general condition, kidney function and hematologic parameters.
• Before this regimen, various premedications are needed to prevent drug-specific adverse effects. High-dose dexamethasone is given before docetaxel to prevent hypersensitivity reactions and fluid retention. It is generally given orally in three 8 mg doses: 12 hours before treatment, 3 hours before treatment and after treatment. This protocol reduces the risk of allergic reactions.
• Before cisplatin, potent antiemetic treatment is given to prevent severe nausea and vomiting. This generally combines 5-HT3 antagonists (e.g., ondansetron or granisetron), NK1 receptor antagonists (e.g., aprepitant or fosaprepitant) and a corticosteroid (usually dexamethasone again). Because cisplatin is nephrotoxic, substantial intravenous fluids before and after treatment (generally hydration with 0.9% NaCl), with a diuretic (e.g., furosemide) when needed, are mandatory to protect the kidneys.
• The administration sequence matters. Docetaxel is generally given first, with an infusion lasting approximately one hour. Cisplatin follows, usually infused over 1 to 2 hours. Additional fluids are given afterward to complete treatment. Hydration, urine output and vital signs should be closely monitored throughout.
• Before each cycle, complete blood count, kidney function (urea, creatinine, creatinine clearance), liver enzymes, electrolytes and performance status must be assessed. Particularly with high neutropenia risk or grade 3–4 myelosuppression in previous cycles, chemotherapy doses may be reduced or supportive treatment with growth factors such as G-CSF (filgrastim) may be started.
• Pre-existing peripheral neuropathy may also worsen with docetaxel. Symptoms of developing nerve damage should be carefully monitored; if neurotoxicity is severe, reduce the dose or change treatment. Similarly, if cisplatin impairs kidney function, it may need to be replaced with a less nephrotoxic agent such as carboplatin. This particularly applies to older, frail patients or those with limited renal reserve.

Situations Requiring Caution

Kidney Function and Cisplatin Nephrotoxicity

• Cisplatin is highly toxic to the kidneys.
• Creatinine, urea and GFR must be checked before treatment.
• For creatinine clearance below 50–60 mL/min, cisplatin is contraindicated or must be replaced with carboplatin.
• Provide substantial fluid loading (hydration) before and after administration and increase urine output.
• Avoid nephrotoxic drugs (NSAIDs, aminoglycosides, etc.).

Myelosuppression and Infection Risk

• Docetaxel carries a significant risk of neutropenia and leukopenia.
• Obtain a complete blood count before each cycle; delay treatment if neutrophils are < 1500/mm³.
• Consider G-CSF (filgrastim, lenograstim) prophylaxis if severe neutropenia risk is high.
• Closely monitor fever, signs of infection and mouth sores.

Hypersensitivity and Anaphylactic Reactions

• Docetaxel carries the hypersensitivity risk associated with taxanes.
• Dexamethasone premedication before treatment is essential.
• If signs of anaphylaxis (rash, dyspnea, hypotension) appear during administration, stop the infusion immediately and give emergency treatment (antihistamines, corticosteroids, adrenaline).

Peripheral Neuropathy

• Cisplatin and taxanes may cause peripheral nerve damage.
• Monitor neurological symptoms such as numbness and tingling in the hands and feet.
• Grade 2 or higher neuropathy requires dose reduction or a drug change.

Hepatotoxicity and Liver Function

• Docetaxel is metabolized in the liver, so doses should be adjusted in patients with elevated liver enzymes (AST, ALT, bilirubin).
• Treatment is contraindicated in severe liver impairment.

Emetogenic Potential and Nausea-Vomiting Management

• Cisplatin carries a high emetogenic risk.
• Use a combination of 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant) and corticosteroids (dexamethasone) before administration.
• Inadequate antiemetic prevention may lead to severe fluid loss and dehydration.

Older and Frail Patients

• In patients over 70, renal reserve, hematologic tolerance and neurological complication risk require greater attention.
• Lower doses or less toxic regimens such as carboplatin + docetaxel may be preferred in these patients.

Pregnancy and Breastfeeding

• Both cisplatin and docetaxel have teratogenic effects (causing congenital abnormalities).
• They are not used during pregnancy or breastfeeding.
• Effective contraception should be used by patients of reproductive age.

Pre-existing Ototoxicity or Ear Problems

• Cisplatin may cause hearing loss (ototoxicity).
• Use caution in patients with prior hearing problems and monitor with audiometry if necessary.

Fluid Retention and Edema

• Docetaxel may cause fluid retention.
• Corticosteroid premedication reduces this risk.
• Patients with heart failure should be closely monitored.

Adverse Effects

• Neutropenia (low white blood cell count): 75–85%, common because of bone marrow suppression; febrile neutropenia risk 10–20%
•  Alopecia (hair loss):  65–85%, generally reversible, with regrowth after treatment ends.
• Nausea-vomiting: 60–80% (cisplatin), cisplatin is highly emetogenic; antiemetic prophylaxis is required.
• Anemia: 40–60%, erythropoietic agents or transfusion may be necessary in severe cases.
• Thrombocytopenia (bleeding risk): 10–30%, generally transient; serious bleeding is rare.
• Peripheral neuropathy: 30–50%, particularly due to cisplatin; numbness and tingling in hands and feet
• Loss of appetite and weight loss: 30–40%, may occur with taste changes.
• Mucositis / Stomatitis: 20–40%, mouth sores, pain and infection risk
• Taste disturbances: 20–30%, reversible; associated with cisplatin.
• Weakness / Fatigue: 50–70%, multifactorial; one of the most commonly reported symptoms.
• Ototoxicity (hearing loss, tinnitus): 10–20% (cisplatin), generally with high doses or cumulative exposure.
• Nephrotoxicity: 10–25% (cisplatin), Reduced GFR, elevated creatinine; preventable with adequate hydration.
• Diarrhea: 10–20%, generally caused by docetaxel; hydration and antidiarrheal treatment may be needed.
• Skin rash / Erythema: 5–15%, mild allergic reactions may occur.
• Hypersensitivity reactions: 5–10% (docetaxel), generally in the first minutes of treatment; prevented with premedication.
• Fluid retention (edema): 10–15% (docetaxel), reduced with corticosteroids.
• Elevated liver enzymes: 5–15%, monitor increases in AST/ALT and bilirubin.